<DOC>
	<DOCNO>NCT02977052</DOCNO>
	<brief_summary>This open-label three-arm phase 2 trial ( include Simon stage 2 design ) consist 90 stage III melanoma patient randomize 1:1:1 receive either 2 course 3 mg/kg ipilimumab + 1 mg/kg nivolumab every 3 week ( Arm A ) , 2 course 1 mg/kg ipilimumab + 3 mg/kg nivolumab every 3 week ( Arm B ) , 2 course ipilimumab 3 mg/kg , directly follow 2 course nivolumab 3 mg/kg every 2 week ( Arm C ) . All three treatment arm apply prior surgery week 6 , 30 patient per arm . Patients stratify accord treatment center . An interim analysis perform 13 patient include arm , thus total 39 patient include .</brief_summary>
	<brief_title>Optimal Neo-adjuvant Combination Scheme Ipilimumab Nivolumab</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>Adults least 18 year age World Health Organization ( WHO ) Performance Status 0 1 Cytologically histologically confirm resectable stage III melanoma one macroscopic lymph node metastasis ( measurable accord RECIST 1.1 ) , biopsied , history intransit metastasis within last 6 month No malignancy , except adequately treat cancerrelated lifeexpectancy 5 year Patient willing undergo triple tumor biopsy extra blood withdrawal screen case relapse No prior immunotherapy target CTLA4 , PD1 PDL1 No immunosuppressive medication within 6 month prior study inclusion Screening laboratory value must meet following criterion : WBC ≥ 2.0x109/L , Neutrophils ≥1.5x109/L , Platelets ≥100 x109/L , Hemoglobin ≥5.5 mmol/L , Creatinine ≤1.5x ULN , AST ≤ 1.5 x ULN , ALT ≤ 1.5 x ULN , Bilirubin ≤1.5 X ULN Normal LDH Women childbearing potential ( WOCBP ) must use appropriate method ( ) contraception . WOCBP use adequate method avoid pregnancy 23 week ( 30 day plus time require nivolumab undergo five halflives ) last dose investigational drug Women childbearing potential must negative serum urine pregnancy test ( minimum sensitivity 25 IU/L equivalent unit HCG ) within 24 hour prior start ipilimumab + nivolumab Men sexually active WOCBP must use contraceptive method failure rate le 1 % per year . Men receive nivolumab sexually active WOCBP instruct adhere contraception period 31 week last dose investigational product Women childbearing potential ( i.e. , postmenopausal ) , surgically sterile well azoospermic men require contraception Patient capable understand comply protocol requirement sign Informed Consent document . Distantly metastasize melanoma History intransit metastasis within last 6 month No measurable lesion accord RECIST 1.1 Subjects active autoimmune disease document history autoimmune disease , history syndrome require systemic steroid immunosuppressive medication , except subject vitiligo resolve childhood asthma/atopy Prior CTLA4 PD1/PDL1 target immunotherapy Radiotherapy prior postsurgery Patients exclude test positive hepatitis B virus surface antigen ( HBV sAg ) hepatitis C virus ribonucleic acid ( HCV antibody ) , indicate acute chronic infection Patients exclude known history test positive human immunodeficiency virus ( HIV ) know acquired immunodeficiency syndrome ( AIDS ) Allergies Adverse Drug Reaction History allergy study drug component History severe hypersensitivity reaction monoclonal antibody Underlying medical condition , Investigator 's opinion , make administration study drug hazardous obscure interpretation toxicity determination adverse event ; Concurrent medical condition require use immunosuppressive medication , immunosuppressive dos systemic absorbable topical corticosteroid ; Use investigational drug study drug administration 30 day 5 halftime study inclusion Pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Melanoma</keyword>
	<keyword>Ipilimumab</keyword>
	<keyword>Nivolumab</keyword>
	<keyword>Neo-adjuvant</keyword>
</DOC>